ReviewJournal of veterinary science2026
Advances in African swine fever vaccine development: challenges and prospects.
Review in Journal of veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Live Attenuated Vaccines for African Swine Fever: Perspectives on Their Use and Strategic Directions.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
importanceAfrican swine fever (ASF) is a devastating transboundary disease of domestic pigs and wild boar, causing severe economic losses with mortality approaching 100% in acute infections. Despite decades of research, there is no widely available, internationally licensed ASF vaccine, and control remains dependent on biosecurity, culling, and movement restrictions. The complex biology of African swine fever virus (ASFV), immune evasion, and incomplete understanding of protective immunity continue to impede vaccine development. OBSERVATIONS: Vaccine development includes live attenuated vaccines (LAVs), subunit vaccines, DNA vaccines, viral vectors, and newer approaches such as virus-like particles (VLPs) and mRNA platforms. LAVs remain the most promising in controlled studies (e.g., BA71ΔCD2) and include candidates with limited emergency authorizations in some settings (e.g., HLJ/18-7GD), but safety concerns (reversion risk), environmental persistence, and DIVA limitations remain major barriers. Subunit and nucleic acid vaccines offer improved safety but have shown limited protection in challenge studies. Advances in structural biology, genomics, and immunology are accelerating rational design, with VLPs emerging as a promising next-generation approach to balance safety and immunogenicity. CONCLUSIONS AND RELEVANCE: Recent progress in ASFV structural understanding, immune correlates of protection, and vaccine engineering supports cautious optimism. Success will likely require standardized evaluation, robust DIVA strategies, and coordinated international development and deployment pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.